Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 3, 2020
Daily News
February 3, 2020
- Astellas’ 9-Month Sales Dip 1.6%, but in Positive Territory If Forex Impact Excluded
February 3, 2020
- Daiichi Sankyo Enjoys 7.7% Rise in April-December Sales; Enhertu Off to Solid Start
February 3, 2020
- Opdivo Sales Drop 4.7% in April-December, but Ono Secures Higher Profits
February 3, 2020
- Chuikyo’s Draft Supplementary Opinions for 2020 Reimbursement Reform Calls for Medical Validity, Cost-Effective Analysis for Prescriptions
February 3, 2020
- CureApp to File Hypertension Treatment App as Early as 2021, PIII Trial Now Underway
February 3, 2020
- Eisai's April-December Operating Profit Surges 28.4% on Lenvima, Guidance Lifted
February 3, 2020
- Asahi Kasei Expands License for iPS Cell-Derived Cartilage Products to Osteoarthritis, Meniscus Injury
February 3, 2020
- Sandoz Completes Aspen Japan Buyout
February 3, 2020
- ViiV Rolls Out HIV Doublet Dovato in Japan
February 3, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…